Digoxin toxicity ECG patterns: from therapeutic effect to life-threatening arrhythmia
Digoxin produces distinct ECG changes at therapeutic levels that must be distinguished from the arrhythmias of toxicity. Understanding both the expected and toxic signatures prevents dangerous misinterpretation in patients on chronic digoxin therapy.
Therapeutic digoxin effect produces the characteristic "digitalis effect" or "Salvador Dalí mustache" appearance: downsloping ST depression with a scooped or sagging morphology, shortened QT interval from accelerated repolarization, and flattened or inverted T-waves in leads with prominent R-waves. These findings are expected in patients receiving digoxin and do not represent toxicity or ischemia. Identifying them correctly prevents unnecessary workup and medication changes.
Digoxin toxicity produces a spectrum of arrhythmias tied to its dual mechanism: increased automaticity (causing ectopy) and decreased AV conduction (causing blocks). The most common toxic arrhythmia is bigeminal PVCs — a pattern of alternating native beats and premature ventricular complexes — which appears because digoxin sensitizes pacemaker cells to triggered activity. Paroxysmal atrial tachycardia with AV block (PAT with block) is nearly pathognomonic for digoxin toxicity when present: the atrial rate is typically 150–250 bpm, and there is 2:1 or variable block at the AV node from digoxin's vagotonic effects. Junctional tachycardia with AV dissociation reflects enhanced automaticity in the AV junctional tissue.
Bidirectional ventricular tachycardia — alternating QRS axis with each beat — is the most severe manifestation of digoxin toxicity and carries high mortality if not recognized immediately. This pattern is so specifically associated with digoxin toxicity and catecholaminergic polymorphic VT (CPVT) that its presence should prompt immediate toxicologic evaluation and consideration of digoxin-specific Fab fragment antibody therapy.
Digoxin level does not perfectly predict toxicity. Clinical toxicity can occur at "therapeutic" levels in patients with hypokalemia, hypomagnesemia, hypothyroidism, or renal impairment. Conversely, some patients tolerate elevated digoxin levels without toxicity. The ECG and clinical presentation guide management decisions alongside the level.
QT prolongation and torsades risk: the drug combinations every nurse must recognize
QT interval prolongation is the ECG substrate for torsades de pointes, a potentially lethal polymorphic ventricular tachycardia. Nurses caring for patients on QT-prolonging medications must understand the risk assessment, the monitoring requirements, and the intervention thresholds.
QTc (corrected QT interval) is the standard monitoring metric. Normal QTc is less than 450 ms in men and less than 470 ms in women. A QTc exceeding 500 ms carries significantly elevated torsades risk and should trigger medication review and electrolyte assessment. A QTc increase of more than 60 ms from baseline is also a clinically significant change regardless of the absolute value.
The QT-prolonging drug categories with highest clinical frequency in hospital settings include: Class IA antiarrhythmics (quinidine, procainamide, disopyramide), Class III antiarrhythmics (amiodarone, sotalol, dofetilide), certain antibiotics (azithromycin, fluoroquinolones — particularly moxifloxacin), antipsychotics (haloperidol, quetiapine, ziprasidone), antiemetics (ondansetron, metoclopramide at high doses), and methadone. The critical safety principle is additivity: each additional QT-prolonging drug increases QTc independently, and two agents with modest individual effects can combine to produce dangerous prolongation.
Drug-drug interactions that amplify QT risk through altered metabolism require specific recognition. Azithromycin combined with fluconazole (which inhibits CYP3A4 metabolism of azithromycin) produces substantially higher azithromycin exposure. Haloperidol at high intravenous doses — a common ICU sedation agent for agitation — has been associated with fatal torsades, particularly in patients with concurrent hypokalemia and receiving other QT-prolonging agents. Nursing assessment should include review of all QT-prolonging agents, electrolyte levels, and baseline QTc before initiating any new QT-prolonging medication.
Sodium channel blockade ECG patterns: TCA overdose, flecainide, cocaine toxicity
Sodium channel blockers produce a characteristic and immediately recognizable ECG pattern that represents a toxicologic emergency. Fast sodium channel blockade slows phase 0 depolarization — the initial rapid upstroke of the action potential — producing QRS widening and specific morphologic changes that predict serious complications.
Tricyclic antidepressant (TCA) overdose is the most clinically important sodium channel blockade scenario in emergency and critical care nursing. The ECG changes of TCA toxicity are specific and prognostically critical. QRS widening greater than 100 ms correlates with seizure risk; QRS widening greater than 160 ms correlates with ventricular arrhythmia risk. A terminal R wave in aVR (positive deflection in the terminal portion of the QRS in lead aVR) greater than 3 mm or an R-to-S ratio in aVR greater than 0.7 is the most specific ECG finding for TCA toxicity and identifies patients at highest risk for seizures and ventricular tachycardia. The treatment is sodium bicarbonate IV — the mechanism is competitive sodium loading (overcomes channel blockade) combined with alkalinization (reduces drug-channel binding).
Class IC antiarrhythmics (flecainide, propafenone) produce use-dependent sodium channel blockade with rate-dependent QRS widening. Flecainide toxicity can cause marked QRS prolongation, a sinusoidal VT pattern, and complete AV block. In patients presenting with wide-complex tachycardia and a history of flecainide use, hypertonic sodium bicarbonate is the specific antidote. The distinction between flecainide-induced wide-complex tachycardia and true ventricular tachycardia has direct management implications.
Cocaine toxicity causes sodium channel blockade through a similar mechanism to TCAs, often combined with adrenergic stimulation producing simultaneous tachycardia and QRS widening. Cocaine-associated chest pain with ECG changes requires both ST-elevation assessment (cocaine causes coronary vasospasm) and QRS width monitoring (sodium channel blockade risk). Calcium channel blockers and beta-blockers are relatively contraindicated because adrenergic stimulation may be protective; sodium bicarbonate and benzodiazepines are preferred for acute toxicity management.
Antiarrhythmic ECG monitoring: what nurses must track for each drug class
Antiarrhythmic medications require ECG monitoring as a core nursing safety responsibility. Each drug class produces expected ECG changes and has toxicity thresholds detectable on the rhythm strip or 12-lead before clinical deterioration occurs.
Beta-blockers decrease heart rate and prolong AV conduction, producing PR interval prolongation and bradycardia at therapeutic doses. Toxicity manifests as high-degree AV block, severe bradycardia, and QRS widening (from sodium channel effects at high doses). The combination of bradycardia, hypotension, and QRS widening in a patient on beta-blocker therapy requires immediate dose assessment and electrolyte review.
Calcium channel blockers (non-dihydropyridine: diltiazem, verapamil) prolong AV nodal conduction at therapeutic doses, producing PR prolongation and rate reduction in Afib. Toxicity causes severe bradycardia, high-degree AV block, junctional rhythm, and hypotension from peripheral vasodilation and negative inotropy. The ECG-specific toxicity signal is progressive PR prolongation leading to Wenckebach patterns or complete AV block.
Amiodarone requires QTc monitoring because its multi-channel blockade prolongs repolarization. Expected QTc prolongation during amiodarone therapy is approximately 60–80 ms. A QTc exceeding 550 ms on amiodarone, or a QTc increase of greater than 100 ms from baseline, suggests excess drug effect and warrants dose assessment. Amiodarone also causes thyroid dysfunction (hyper and hypothyroidism), pulmonary toxicity, and hepatotoxicity — the ECG monitors the cardiac component while other organ systems require separate surveillance.